Evidence map›Paper›PMID 40943160›Full record

ArticleInternational journal of molecular sciences2025

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.

Sedigheh Givi, Benedikt J Lohnes, Saber Ebrahimi, Sophie Riedel, Sneha Khokhali, Shamsul A Khan, Maximilian Keller, Catherine Wölfel, Hakim Echchannaoui, Ernesto Bockamp and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sedigheh GiviDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
Benedikt J LohnesDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.ORCID 0009-0006-3362-6546
Saber EbrahimiDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
Sophie RiedelDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
Sneha KhokhaliDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
Shamsul A KhanDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
Maximilian KellerDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.ORCID 0009-0001-9092-6290
Catherine WölfelDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
Hakim EchchannaouiDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
Ernesto BockampResearch Center for Immunotherapy, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.
Maya C AndreDepartment of Hematology/Oncology and General Pediatrics, Children's University Hospital, University of Tübingen, 72074 Tübingen, Germany.
Hinrich AbkenDivision Genetic Immunotherapy, Leibniz Institute for Immunotherapy, 93053 Regensburg, Germany.ORCID 0000-0002-4302-3240
Matthias TheobaldDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.ORCID 0000-0002-4270-2209
Udo F HartwigDepartment of Medicine, Hematology & Medical Oncology, University Medical Center of Johannes Gutenberg University, 55101 Mainz, Germany.ORCID 0000-0002-6714-6923

Funding

Wilhelm-Sander-Stiftung 2022.046.1
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T-cell therapy directed to CD19 and B-cell maturation antigen has revolutionized treatment of B-cell leukemia and lymphoma, and multiple myeloma. However, identifying suitable targets for acute myeloid leukemia (AML) remains challenging due to concurrent expression of potential target antigens on normal hematopoietic stem cells or tissues. As the stress-induced B7H6 molecule is rarely found on normal tissues but expressed on many cancers including AML and melanoma, the NKp30-ligand B7H6 emerges as a promising target for NKp30-based CAR T therapy for these tumors. In this study, we report a comprehensive B7H6 expression analysis on primary AML and melanoma as well as on different tumor cell-lines examined by RT-qPCR and flow cytometry, and efficient anti-tumor reactivity of NKp30-CAR T cells to AML and melanoma. To overcome limitations of autologous CAR T-cell fitness-dependent efficacy and patient-tailored production, we generated CRISPR/Cas9-mediated TCR-knockout (TCR

Indexed as

B7 AntigensCRISPR-Cas SystemsImmunotherapy, AdoptiveLeukemia, Myeloid, AcuteMelanomaNatural Cytotoxicity Triggering Receptor 3Receptors, Antigen, T-CellReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorHumansMiceXenograft Model Antitumor AssaysB7 AntigensNatural Cytotoxicity Triggering Receptor 3NCR3 protein, humanReceptors, Antigen, T-CellReceptors, Chimeric Antigenacute myeloid leukemiaB7H6 expressing tumorsCAR T-cell therapyimmunotherapymelanomaNKp30-based CAR T-cell therapy

Identifiers

PMID40943160
PMCPMC12428420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.